乙型肝炎肝硬化合并骨质疏松患者临床干预的安全性研究OA

Objective:To explore the safety of antiviral therapy and anti-osteoporosis therapy in patients with hepatitis B cirrhosis combined with osteoporosis.Methods:74 patients with hepatitis B cirrhosis complicated with osteoporosis admitted to our hospital from January 2020 to December 2022 were selected as the study objects,and were divided into a control group and an experimental group according to random number table method,with 37 cases in each group.The control group was treated with antiviral drugs,and the experimental group was treated with anti-osteoporosis drugs based on the control group.Liver function,viral load,liver hardness,bone mineral density at key sites and adverse reactions were compared between the two groups.Results:At admission,6 and 12 months after admission,there were no significant differences in liver function,viral load and liver hardness between the two groups(P>0.05).6 and 12 months after admission,BMD of lumbar L2～4 and femoral neck in experimental groups were greater than those in control group,and the differences between groups were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:Simultaneous administration of antiviral and anti-osteoporosis drugs in patients with hepatitis B cirrhosis combined with osteoporosis is safe,and increased use of anti-osteoporosis drugs can improve the condition of osteoporosis without adverse effects on the liver function of patients.